ClinicalTrials.gg
RecruitingNCT07842835CLIMBUpdated Nov 10, 2026

Registry of an Integrated Longitudinal Multimodal Biospecimen Biobank for Primary CNS Lymphoma in China

An observational study in Primary Central Nervous System Lymphoma (PCNSL), sponsored by Xiaohui Ren. Recruiting at 3 sites in China. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Xiaohui Ren · Observational

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Sep 30, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
18 Years to 100 Years
Sex
All
01

Study summary

This project aims to establish and prospectively register a longitudinal, multimodal biobank for primary central nervous system lymphoma (PCNSL). The study will primarily enroll patients undergoing needle biopsy or surgical resection of lesions involving the brain, spinal cord, or meninges, with a pathological diagnosis of central nervous system lymphoma. To ensure population homogeneity, patients with PCNSL will constitute the core analysis cohort. Patients with imaging findings suggestive of PCNSL but a final pathological diagnosis other than PCNSL will serve as disease controls, and matched healthy volunteers will be recruited as baseline controls.

At baseline, biopsy tissue, cerebrospinal fluid (CSF), peripheral blood, urine, saliva, and stool samples will be collected. Follow-up visits will be scheduled at 1 month after biopsy and every 3-6 months thereafter, with contrast-enhanced brain magnetic resonance imaging (MRI) and serial collection of CSF and peripheral blood. After the requirements of routine pathological diagnosis have been met, biopsy specimens will undergo tiered multi-omics profiling according to sample availability and freshness, including whole-exome sequencing, bulk RNA sequencing, single-cell RNA sequencing, metabolomics, spatial transcriptomics, and spatial metabolomics. Analyses of CSF and blood samples will focus on circulating tumor DNA and cell-free RNA (ctDNA/cfRNA), supplemented by conventional cytology, flow cytometry, and other clinical data for longitudinal disease monitoring.

The project will develop an integrated database incorporating clinical, imaging, pathological, molecular, and biospecimen data. It will characterize the relationships of baseline tissue multi-omics features and longitudinal changes in CSF- and blood-derived ctDNA/cfRNA with treatment response, recurrence prediction, and prognosis. The study will also develop diagnostic and risk-stratification models applicable to patients at our institution, across the region, and potentially throughout mainland China, while establishing standardized operating procedures for biospecimen collection and processing. This work is expected to provide high-quality evidence and a sustainable translational research platform for elucidating the biological heterogeneity of PCNSL, validating liquid-biopsy biomarkers, and optimizing precision follow-up strategies.

02

Conditions studied

  • Primary Central Nervous System Lymphoma (PCNSL)

Keywords

  • Primary central nervous system lymphoma
  • Multimodal biobank
  • Prospective longitudinal cohort
  • Liquid biopsy
  • Circulating tumor DNA
  • Cell-free RNA
  • Multi-omics
  • Recurrence prediction
03

In context

Lead sponsor

Xiaohui Ren is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will be drawn from patients evaluated for suspected primary central nervous system lymphoma at participating tertiary referral hospitals in mainland China, including Beijing Tiantan Hospital, Shandong Provincial Hospital, and Tianjin Huanhu Hospital. Participants will be identified through departments of neurosurgery, hematology, neuro-oncology, radiology, and pathology. Healthy controls will be recruited from the participating institutions and surrounding communities to provide reference biospecimens and molecular profiles. The study will include a core PCNSL cohort, a non-PCNSL disease-control cohort, and a nested longitudinal cerebrospinal fluid/peripheral blood subcohort.

Eligibility criteria

Inclusion Criteria:

  • General Criteria for Patient Participants
  • Age ≥18 years.
  • Radiological findings suspicious for primary central nervous system lymphoma (PCNSL).
  • Scheduled to undergo needle or surgical resection of a lesion involving the brain, spinal cord, or meninges.
  • Willing and able to provide written .
  • Core PCNSL Cohort
  • Patient participants must additionally meet all of the following criteria:
  • Histopathologically confirmed PCNSL.
  • Able and willing to comply with scheduled study follow-up.
  • Able to undergo magnetic resonance imaging examinations.
  • Non-PCNSL Disease Control Cohort
  • Patient participants must meet the following criterion:
  • Initially suspected of having PCNSL based on imaging findings but ultimately diagnosed with a condition other than PCNSL by histopathological examination.
  • Healthy Control Cohort
  • Age ≥18 years.
  • Eligible for recruitment as a healthy control according to the study screening procedures.
  • Meets the prespecified matching requirements for the study cohorts.
  • Willing and able to provide written informed consent.
  • Additional Criteria for the Longitudinal CSF/Peripheral Blood Subcohort
  • Participants entering this subcohort must additionally meet all of the following criteria:
  • No to lumbar puncture, as determined by the study physician.
  • Willing and able to undergo serial cerebrospinal fluid and peripheral blood collection.
  • Provides separate explicit informed consent for longitudinal biospecimen collection.
  • Final eligibility for all cohorts will be determined by the study investigator based on the participant's clinical condition, pathological findings, and relevant examination results.

Exclusion Criteria:

  • Exclusion Criteria for Patient Cohorts
  • PCNSL is suspected based on imaging findings, but no definitive histopathological diagnosis can be obtained.
  • Estimated of less than 3 months and, in the investigator's judgment, inability to complete the minimum required clinical data or biospecimen collection.
  • Refusal to provide written informed consent or withdrawal of informed consent.
  • Additional Exclusion Criteria for the Longitudinal CSF/Peripheral Blood Subcohort
  • Participants will be excluded from research lumbar puncture if any of the following conditions are present:
  • Severe coagulation disorder.
  • Marked or severe intracranial hypertension.
  • Evidence of, or substantial risk for, cerebral herniation.
  • Spinal infection or central nervous system infection.
  • Any other definite contraindication to lumbar puncture, as determined by the investigator.

Exclusion Criteria for Healthy Controls

  • Presence of a severe systemic disease.
  • Any condition that, in the investigator's judgment, makes the individual unsuitable for participation.
  • Refusal to provide written informed consent or withdrawal of informed consent.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • PCNSL Cohort

    Adults with pathologically confirmed primary central nervous system lymphoma (PCNSL) following biopsy or surgical resection of a brain, spinal cord, or meningeal lesion. Clinical, imaging, pathological, treatment, and outcome data will be collected. Tumor tissue, cerebrospinal fluid, peripheral blood, urine, saliva, and stool will be collected at baseline, as available. Eligible consenting participants without contraindications to lumbar puncture may enter a longitudinal biospecimen subcohort, with contrast-enhanced brain MRI and serial cerebrospinal fluid and peripheral blood collection at postoperative Month 1 and every 3-6 months thereafter.

    Drug: High-dose methotrexate-based therapy · Drug: Bruton tyrosine kinase inhibitor-based therapy

Interventions

  • DrugHigh-dose methotrexate-based therapy

    Standard-of-care treatment containing high-dose methotrexate as the backbone regimen, administered alone or in combination with other anticancer agents according to the treating physician's judgment and institutional practice. Treatment selection, dose, schedule, combination regimen, and duration are not assigned by the study protocol. Clinical response, recurrence, survival, adverse events, imaging findings, and longitudinal molecular biomarkers will be recorded prospectively.

  • DrugBruton tyrosine kinase inhibitor-based therapy

    Standard-of-care treatment containing a Bruton tyrosine kinase inhibitor as a principal therapeutic component, administered alone or in combination with other anticancer agents according to the treating physician's judgment and institutional practice. The specific BTK inhibitor, dose, schedule, combination regimen, and duration are not assigned by the study protocol. Clinical response, recurrence, survival, adverse events, imaging findings, and longitudinal molecular biomarkers will be recorded prospectively.

06

What researchers measure

Primary outcomes

  1. Baseline data completeness rate

    Percentage of enrolled participants with complete required baseline clinical, imaging, pathological, treatment, and biospecimen information in the electronic case report form. The numerator is the number of participants with all protocol-required baseline data; the denominator is the total number of enrolled participants.

    Time frame: At baseline, from enrollment through completion of baseline assessments(up to 30 months)

  2. Paired tumor tissue and cerebrospinal fluid sample acquisition rate

    Percentage of eligible participants from whom both evaluable tumor tissue and cerebrospinal fluid samples are successfully collected and stored according to the study standard operating procedures.

    Time frame: within 1 month after biopsy or surgery (up to 30 months)

  3. Participant follow-up completion rate

    Percentage of enrolled participants who complete the protocol-required clinical and imaging follow-up assessments at Month 12 and Month 24. Completion rates will be calculated separately for each time point.

    Time frame: from enrollment to follow-up at Month 3, 6, 12, 24 and 36 (up to 36 months)

  4. Adherence to longitudinal cerebrospinal fluid sampling

    Percentage of scheduled cerebrospinal fluid collection visits completed among participants enrolled in the longitudinal cerebrospinal fluid/peripheral blood subcohort.

    Time frame: Postoperative Month 1 and every 3-6 months thereafter (up to 36 months)

  5. Association between cerebrospinal fluid ctDNA clearance and MRI response

    Cerebrospinal fluid circulating tumor DNA status will be classified as cleared or not cleared at postoperative Month 3 and compared with concurrent MRI response categories-complete response, partial response, stable disease, or progressive disease. The association or agreement will be assessed using contingency-table analysis, kappa statistics, and/or receiver operating characteristic analysis, as applicable.

    Time frame: 3-6 months after pathological comfirmation (up to 36 months)

  6. Association of baseline and longitudinal ctDNA/cfRNA status with progression-free survival

    Progression-free survival will be evaluated according to baseline and longitudinal cerebrospinal fluid or peripheral blood ctDNA/cfRNA status. Progression-free survival is the time from the prespecified index date to radiographic or clinical disease progression or death from any cause, whichever occurs first.

    Time frame: From the prespecified index date through Month 3, 6, 12, 24 and 36 (up to 36 months)

Secondary outcomes

  1. Objective response rate

    Percentage of evaluable participants achieving complete response or partial response on MRI, summarized according to prespecified baseline tumor multi-omics characteristics.

    Time frame: From treatment initiation to follow-up at month 3,6,12,24 and 36 (up to 36 months)

  2. Best overall response

    Best MRI response recorded during follow-up-complete response, partial response, stable disease, or progressive disease-summarized according to baseline tumor multi-omics characteristics.

    Time frame: From treatment initiation to follow-up at month 3,6,12,24 and 36 (up to 36 months)

  3. Progression-free survival

    Time from the prespecified index date to radiographic or clinical progression or death from any cause, whichever occurs first, analyzed according to baseline tumor multi-omics characteristics.

    Time frame: From treatment initiation to follow-up at month 3,6,12,24 and 36 (up to 36 months)

  4. Overall survival

    Time from the prespecified index date to death from any cause. Participants without a documented death will be censored at the date they were last known to be alive.

    Time frame: From treatment initiation to follow-up at month 3,6,12,24 and 36 (up to 36 months)

  5. Lead time from molecular recurrence detected by cerebrospinal fluid ctDNA to radiographic recurrence

    Number of days between the first post-clearance cerebrospinal fluid ctDNA reappearance or prespecified increase in variant allele fraction and the date of MRI-confirmed disease recurrence. Positive values indicate that molecular recurrence preceded radiographic recurrence.

    Time frame: Postoperative Month 1 and every 3 months thereafter (up to 36 months)

  6. Concordance and clinical associations of key driver variants in tumor tissue and cerebrospinal fluid

    Concordance of key driver variants, including MYD88, between tumor tissue and cerebrospinal fluid ctDNA, and their associations with pathological subtype, treatment regimen, response, progression, and survival.

    Time frame: At baseline and every 3-6 months after pathological confirmation (up to 36 months)

  7. Molecular evolution between diagnosis and recurrence

    Changes in somatic variants, variant allele fractions, copy-number alterations, transcriptomic features, or other prespecified molecular characteristics between paired diagnostic and recurrence samples.

    Time frame: From baseline to the first documented recurrence (up to 36 months)

  8. Change in neurological and performance status

    Change from baseline in neurological function and performance status, including Karnofsky Performance Status and/or Eastern Cooperative Oncology Group performance status.

    Time frame: At baseline and every 3-6 months thereafter (up to 60 months)

  9. Change in cognitive function

    Change from baseline in cognitive function measured using a prespecified validated cognitive assessment instrument.

    Time frame: At baseline and every 3 months thereafter (up to 60 months)

  10. Incidence of treatment-related adverse events

    Number and percentage of participants experiencing treatment-related adverse events, summarized by event type, severity, and relationship to treatment using a prespecified adverse-event grading system.

    Time frame: From enrollment to follow-up (up to 36 months)

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Dec 2028, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Sep 25, 2026
StartActual
Oct 1, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Jul 31, 2031
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 30, 2026
Sites
3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • Deparment of neurosurgery, Beijing tiantan hospital · Beijing, Chinano status→Recruiting
  • Deparment of neurosurgery, Shandong Provincial Hospital · Shandong, Chinano status→Recruiting
  • Deparment of neurosurgery, Tianjin huanhu hospital · Tianjin, Chinano status→Recruiting
Sep 30, 2026
Title
Registry of an Integrated Longitudinal Multimodal Biospecimen Biobank for Primary CNS Lymphoma in China (CLIMB)
Sep 30, 2026
Registered
First appeared on the registry
Sep 25, 2026
Show all 3 updates
  1. Nov 10, 2026
    Minor edits only
    + 2 other changes: verification date and date precision
  2. Sep 30, 2026
    Not yet recruiting→Recruiting
    3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Deparment of neurosurgery, Beijing tiantan hospital · Beijing, Chinano status→Recruiting
    • Deparment of neurosurgery, Shandong Provincial Hospital · Shandong, Chinano status→Recruiting
    • Deparment of neurosurgery, Tianjin huanhu hospital · Tianjin, Chinano status→Recruiting
    Title Registry of an Integrated Longitudinal Multimodal Biospecimen Biobank for Primary CNS Lymphoma in China (CLIMB)
    + 1 other change: criteria formatting
  3. Sep 25, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07842835
Lead sponsor
Xiaohui Ren
Collaborators
Shandong Provincial Hospital, Tianjin Huanhu Hospital
Responsible party
Xiaohui Ren (Department of Neurosurgery, Beijing Tiantan Hospital, Beijing Tiantan Hospital) — Sponsor-investigator
First posted
Sep 25, 2026
Start date
Oct 1, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Jul 31, 2031 (estimated)
Last update
Nov 10, 2026

Study contacts

Xiaohui Ren, MD
Contact
xiaohuiren@mail.ccmu.edu.cn/xiaohuiren@aliyun.com
+86-010-59975567
Haoyi Li, MD
Contact
lee_627269051@163.com
+86-010-59975567

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion